news, journals and articles from all over the world.
Researchers from PNNL have helped colleagues at OHSU identify lipid molecules required for Zika infection in human cells. The specific lipids involved could also be a clue to why the virus primarily infects brain tissue.
Read more
Johns Hopkins researchers have received $35 million in funding from the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the Defense Health Agency, for two nationwide clinical trials to test the effectiveness of a convalescent blood plasma outpatient treatment. The treatment is a transfusion of a blood product from COVID-19 survivors that contains antibodies that may help the patient’s immune system fight the virus.
Read more
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
The method reveals that the lattice, which forms the major structural component of the human immunodeficiency virus (HIV), is dynamic. The discovery of a diffusing lattice made from Gag and GagPol proteins, long considered to be completely static, opens up potential new therapies. The method can be applied to biomedical structure.
Read more
A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.
Read moreEducators could use the COVID-19 outbreak to help middle-schoolers better understand the world, according to new research from faculty at Binghamton University, State University of New York.
Read more
Can antibiotic-resistant bacteria escape from sewers into waterways and cause a disease outbreak? A new Rutgers study, published in the journal Environmental Science: Water Research & Technology, examined the microbe-laden “biofilms” that cling to sewer walls, and even built a simulated sewer to study the germs that survive within.
Read more
A study of 3,268 hospitals in the U.S. shows that rural hospitals are more likely than urban facilities to have access to telehealth, a once-underused service that now is playing a key role in treating coronavirus patients. The research can help U.S. hospitals understand the extent to which they are prepared for another wave of the pandemic.
Read moreResearchers at Binghamton University, State University of New York are using machine learning to track the coronavirus and predict where it might surge next.
Read more
In response to the high demand for one of the fastest-growing jobs in the U.S., FAU has launched a new, online public health certificate course on COVID-19, contact tracing and risk-reduction. The five-week, 15-hour course does not require a college degree and is scheduled from June 29 to Aug. 7. The program is open to the general public for adults age 18 and older with a high school diploma or equivalent and a variety of work experiences and educational backgrounds.
Read more
One of the many questions researchers have about the COVID-19 virus is how long it remains alive after someone infected coughs or sneezes. In Physics of Fluids, researchers examine the drying time of respiratory droplets from COVID-19-infected subjects on various surfaces in six cities around the world. Using a model well established in the field of interface science, the drying time calculations showed ambient temperature, type of surface and relative humidity play critical roles.
Read more
Scientists at Berkeley Lab and Stanford have joined forces to aim a gene-targeting, antiviral agent called PAC-MAN against COVID-19.
Read more